Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Storr

Showing results (111-120 of 157) with videos related to

Pageof 16
Sort By:
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 1, 2020
Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tractAgata Szymaszkiewicz, Jakub Włodarczyk, Andrzej Wasilewski, et al.
Phytotherapy Research : PTR|January 3, 2007
The Chinese herbal preparation Qing Yi Tang (QYT) improves intestinal myoelectrical activity and increases intestinal transit during acute pancreatitis in rodentsYong-Yu Li, Andrei Sibaev, Ming-Zheng Zhou, et al.
Deutsche Medizinische Wochenschrift (1946)|August 12, 2015
[Fecal microbiota transfer (FMT) in a patient with refractory irritable bowel syndrome]Verena Zoller, Anna-Lena Laguna, Olivia Prazeres Da Costa, et al.
Nature Reviews. Gastroenterology & Hepatology|September 28, 2022
Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndromeStuart M Brierley, Beverley Greenwood-Van Meerveld, Giovanni Sarnelli, et al.
European Journal of Pharmacology|September 15, 2019
Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]Maciej Salaga, Agata Binienda, Ritesh B Tichkule, et al.
European Journal of Pharmacology|August 20, 2018
The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndromeMaciej Salaga, Agata Binienda, Ritesh B Tichkule, et al.
Plos One|March 3, 2010
The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's diseaseMartin Storr, Dominik Emmerdinger, Julia Diegelmann, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 10, 2012
Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanismsThomas Michler, Martin Storr, Johannes Kramer, et al.
Peptides|May 4, 2010
Synthesis and biological evaluation of novel peripherally active morphiceptin analogsKatarzyna Gach, Jean Claude do-Rego, Jakub Fichna, et al.
Wiener Medizinische Wochenschrift (1946)|April 21, 2017
Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disordersAhmed Madisch, Bettina R Vinson, Heba Abdel-Aziz, et al.
Pageof 16

Showing results (111-120 of 157) with videos related to

Sort By:
Pageof 16
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 1, 2020
Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tractAgata Szymaszkiewicz, Jakub Włodarczyk, Andrzej Wasilewski, et al.
Phytotherapy Research : PTR|January 3, 2007
The Chinese herbal preparation Qing Yi Tang (QYT) improves intestinal myoelectrical activity and increases intestinal transit during acute pancreatitis in rodentsYong-Yu Li, Andrei Sibaev, Ming-Zheng Zhou, et al.
Deutsche Medizinische Wochenschrift (1946)|August 12, 2015
[Fecal microbiota transfer (FMT) in a patient with refractory irritable bowel syndrome]Verena Zoller, Anna-Lena Laguna, Olivia Prazeres Da Costa, et al.
Nature Reviews. Gastroenterology & Hepatology|September 28, 2022
Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndromeStuart M Brierley, Beverley Greenwood-Van Meerveld, Giovanni Sarnelli, et al.
European Journal of Pharmacology|September 15, 2019
Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]Maciej Salaga, Agata Binienda, Ritesh B Tichkule, et al.
European Journal of Pharmacology|August 20, 2018
The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndromeMaciej Salaga, Agata Binienda, Ritesh B Tichkule, et al.
Plos One|March 3, 2010
The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's diseaseMartin Storr, Dominik Emmerdinger, Julia Diegelmann, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 10, 2012
Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanismsThomas Michler, Martin Storr, Johannes Kramer, et al.
Peptides|May 4, 2010
Synthesis and biological evaluation of novel peripherally active morphiceptin analogsKatarzyna Gach, Jean Claude do-Rego, Jakub Fichna, et al.
Wiener Medizinische Wochenschrift (1946)|April 21, 2017
Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disordersAhmed Madisch, Bettina R Vinson, Heba Abdel-Aziz, et al.
Pageof 16